Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | PRKCA | P17252 | 4/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.53 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | DGKA | P23743 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715876 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL3250346 | 1.00 | MAPT (0.60) | MAPTMAPK1LMNAPRKCAPRKCE | |
| Ethylene SCHEMBL21633977 | 0.97 | MAPT (0.57) | MAPTMAPK1LMNAPRKCAPRKCE | |
| Ethylene SCHEMBL7947908 | 0.97 | MAPT (0.57) | MAPTMAPK1LMNAPRKCAPRKCE | |
| Oxirane SCHEMBL7557475 | 0.93 | MAPT (0.53) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL30932044 | 0.92 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL10539866 | 0.92 | MAPT (0.66) | MAPTMAPK1LMNAPRKCAPRKCE | |
| SCHEMBL714739 | 0.92 | PRKCA (0.59) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| SCHEMBL709550 | 0.92 | PRKCA (0.59) | MAPTMAPK1PRKCAPRKCEPRKCQ | |
| Propylene Oxide SCHEMBL6941925 | 0.89 | MAPT (0.49) | MAPTMAPK1LMNAPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416579-A1 | AEROSOL RAW MATERIAL COMPOSITION, AEROSOL COMPOSITION, AND AEROSOL PRODUCT | AGC Inc. (JP) | 2023-12-28 | — | — | US | disclosed |
| US-20230404877-A1 | POWDER-CONTAINING COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 2023-12-21 | — | — | US | disclosed |
| US-11827004-B2 | Method and device for producing foamed body | RICOH COMPANY, LTD. (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20230293417-A1 | ADENOSINE-CONTAINING COMPOSITION AND METHOD FOR SUPPRESSING PRECIPITATION OF ADENOSINE | SHISEIDO COMPANY, LTD. (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-3760198-B1 | DICLOFENAC-CONTAINING EMULSIFIED GEL COMPOSITION | HISAMITSU PHARMACEUTICAL CO (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-3666251-B1 | POWDER-CONTAINING WATER-BASED COMPOSITION AND EXTERNAL SKIN PREPARATION | SHISEIDO CO LTD (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-4233835-A1 | OIL-IN-WATER TYPE COMPOSITION | Shiseido Company, Ltd. (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-11730684-B2 | Cleansing composition | SHISEIDO COMPANY, LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| EP-2740771-B1 | COMPOSITE POWDER AND METHOD FOR PRODUCING SAME | SAKAI CHEMICAL INDUSTRY CO (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-20230190626-A1 | CLEANSER COMPOSITION | SHISEIDO COMPANY, LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | RESONAC CORPORATION (JP) | 2008-04-10 | — | — | US | disclosed |
| EP-1896139-A2 | PERMANENT WAVING AND SIMULTANEOUSLY COLORING AGENT | Showa Denko K.K. (JP) | 2008-03-12 | — | — | EP | disclosed |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | SHISEIDO COMPANY LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070190009-A1 | Hair Cosmetic Composition | SHISEIDO CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1810657-A1 | HAIR CARE PREPARATIONS | SHISEIDO COMPANY, LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006121214-A2 | PERMANENT WAVING AND SIMULTANEOUSLY COLORING AGENT | SHOWA DENKO K.K. (JP) | 2006-11-16 | — | — | WO | disclosed |
| EP-1688126-A1 | PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN | SHISEIDO COMPANY LIMITED (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20030003071-A1 | Hair growth stimulant | SHISEIDO COMPANY, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1234574-A1 | HAIR GROWTH STIMULANT | SHISEIDO COMPANY LIMITED (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-4520008-A | ADDITION POLYMER AND PROPYLENE OXIDE-ETHYLENE OXIDE ADDUCT OF A FATTY ALCOHOL; TEXTURE | KAO SOAP CO., LTD. (JP) | 1985-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190009-A1 | Hair Cosmetic Composition | H1-10, H1-0, H1-4 | MAPT 4217/4885MAPK1 2870/4885LMNA 1023/4885 |
| US-11730684-B2 | Cleansing composition | DEGS1, SGMS2, SGMS1 | MAPT 4656/4885MAPK1 3526/4885LMNA 916/4885 |
| US-20230190626-A1 | CLEANSER COMPOSITION | MGLL, SGMS2, DAGLB | MAPT 4842/4885MAPK1 4620/4885LMNA 2227/4885 |
| US-20070225380-A1 | Parakeratosis Inhibitor and Skin Preparation for External use | CUTA, HPN, DNPEP | MAPT 4709/4885MAPK1 2285/4885LMNA 147/4885 |
| US-20080085251-A1 | even at a neutral to weakly acidic pH; a lactone or lactam having a mercapto group; with thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine; | TST, CYSLTR1, CYSLTR2 | MAPT 4300/4885MAPK1 3014/4885LMNA 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.